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The presence or development of ultrafiltration failure by pathophysiologic mechanisms. This classification will
(UFF) in patients on peritoneal dialysis (PD) has been serve as a framework for the discussion of the role of
the subject of increasing interest in the renal literature icodextrin in helping correct the resultant clinical conse-
and the understanding of its causes and therapies contin- quences.
ues to evolve [1–7]. An important aspect of these new
insights is the greater clarity in definition and the recogni-
UF FAILURE DURING TRANSIENT HIGHtion that clinical failure in maintaining volume homeosta-
TRANSPORT: PERITONITISsis needs to be separated from true failure of ultrafiltra-
Clinical and transport changestion at the level of the peritoneal membrane [1–7]. This
is particularly important because the refinement in the Loss of UFC is a common clinical observation during
techniques of peritoneal dialysis, the greater reliance on episodes of peritonitis. Patients frequently exhibit nega-
automation, and the introduction of new osmotic agents tive net ultrafiltration with fluid retention and weight
have led to resolution of conditions that would have pre- gain. Use of very hypertonic glucose solutions is common
viously been labeled as ultrafiltration failure. The proper in the early stages of peritonitis, and adjustments in pre-
incidence of ultrafiltration failure, however, is at present scriptions are usually required until the inflammatory
difficult to determine because of the variability in case process has completely abated. Evaluations of transport
definition. If one considers failure of the peritoneal re- parameters during episodes of clinical peritonitis have
sponse to a 3.86%/4.25% glucose solution as an opera- revealed several changes in transport characteristics that
tional definition, then the incidence is rather low, espe- are summarized in Table 2 and illustrated in Figures 1,
cially during the first years of PD. However, if failure to 2, and 3.
achieve volume homeostasis is the criterion used, then Detailed clinical evaluation of transport changes have
a larger number of patients may be at risk of being la- been carried out in a limited number of studies [8, 9]. This
beled as having UFF. With the increasing tendency to is partly explained by the logistic hurdles of physiologic
tailor PD modality selection (CAPD vs. APD) to individ- evaluations in acutely ill patients. Nevertheless, the avail-
ual patient characteristics, and wide utilization of icodex- able data provide a clear delineation of the transport
trin, it is likely that older prevalence data will become changes, and these findings have been corroborated by
irrelevant to guide current clinical practice. observations in experimental animals. Only a few recent
The term loss of ultrafiltration capacity (UFC) has representative studies will be reviewed herein.
been used as a more precise term to help distinguish the Douma et al recently described the transport conse-
clinical syndrome of fluid overload from a pathophysio- quences of peritonitis in fifteen patients undergoing con-
logic alteration in the peritoneal membrane [2]. Such a tinuous ambulatory peritoneal dialysis (CAPD) with 16
precision is a felicitous development, and it is hoped that peritonitis episodes [9]. Patients were evaluated during
greater appreciation of the need for precise definition the acute phase of the infection and after recovery by stan-
will allow the use of the term ultrafiltration failure to be dard peritoneal permeability analyses [10]. The mass
limited to conditions associated with loss of ultrafiltration transfer area coefficients (MTACs) of low-molecular-
capacity. It is in this sense that the term ultrafiltration weight solutes increased during peritonitis: urea 26%,
failure is used in the present article. creatinine 45%, and urate 45%. The MTAC of CO2,
Table 1 offers a classification of ultrafiltration failure calculated to estimate peritoneal blood flow, was 71 mL/
min (34 to 254 mL/min) during peritonitis and 55 mL/min
(42 to 63 mL/min) after recovery, reflecting an increase inKey words: renal replacement therapy, dialysate, volume homeostasis,
CAPD, APD, peritoneal dialysis. peritoneal perfusion. The peritoneal protein clearances
were also greater during peritonitis, but this increase was 2002 by the International Society of Nephrology
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Table 1. Pathophysiologic classification of peritoneal causes of
ultrafiltration failure
Mechanism Condition
Rapid dissipation of glucose Fast transport status
osmotic gradient
Defects in fluid pathways Impaired aquaporin function
Exaggerated contrary mechanisms Lymphatic/tissue reabsorption
Loss of functional peritoneum Adhesions
Fig. 2. Peritonitis results in a sharp decline in dialysate glucose and a
parallel decline in net ultrafiltration, both changes being progressiveTable 2. Transport changes during peritonitis
with time. In long dwells (8 hours) the net ultrafiltration in rats with
peritonitis becomes negative. Symbols are: () control; () peritonitis.Parameter Change in MTAC References
Data are from reference [32].
CO2 ↑ [9]
Urea ↑ [8, 9, 11]
Creatinine ↑ [8, 9, 11]
Urate ↑ [9]
Glucose ↑ [8, 9, 11]
Fig. 3. The sharp decline in net ultrafiltration during peritonitis leads
to the obliteration of the decline in dialysate sodium that is usually the
result of water ultrafiltration via aquaporins. This is not due to any
decline in the expression of aquaporins, but rather to their function or
to increased sodium diffusion. Data are from reference [14].
Fig. 1. In rats with lipopolysaccharide (LPS)-induced peritonitis, a sig-
nificant increase was found in the diffusive transport measures for small
solutes. Data are from reference [11].
inflammatory conditions are associated with enhanced
lymphatic absorption has led to the lingering misconcep-
tion that this mechanism may be operative in peritoni-not related to the molecular weight of the protein. The
tis as well. This has been disproved by several studiesnet ultrafiltration in all peritonitis episodes was lower as
[11, 12] including the recent work of Carlsson and Rippecompared with the control dwells [9].
[13]. They found that zymosan-induced peritonitis in ex-These clinical observations have been duplicated by
perimental animals led to a marked increase in massseveral experimental studies. Wang et al recently exam-
transfer area coefficients for small solutes (Fig. 4). Thisined the transport changes in an experimental model of
was paralleled by an increase of plasma-to-dialysate pro-peritonitis induced in rats by the intraperitoneal injection
tein clearance (a measure of protein leak), and a declineof lipopolysaccharide (LPS) [11]. The small solute diffu-
in peritoneal-to-plasma labeled protein clearance (asive transport rates were, in general, increased during
measure of lymphatic absorption). Despite marked ef-peritonitis as compared with control (Fig. 1). The dialy-
sate osmolality decreased much faster in the LPS treated fects on peritoneal solute transport and on ultrafiltration,
conceivably resulting from vasodilatation and increasesgroup as compared with control, resulting in significantly
lower transcapillary ultrafiltration. In LPS injected ani- in capillary permeability, zymosan-induced peritonitis did
not cause any acute increases in the plasma appearancemals, net ultrafiltration was significantly lower (by 44%)
as compared with the control group [11]. rate of IP instilled labeled albumin.
Taken together, clinical and experimental observa-It is clear from clinical and experimental evidence that
the loss of ultrafiltration capacity during peritonitis is tions identify the ultrafiltration failure of peritonitis as
a state of acute, transient, very high transport induced bydue predominantly to the rapid dissipation of the glu-
cose-dependent osmotic gradient. The observation that the inflammatory process.
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Fig. 5. Peritonitis is associated with an increase in both endothelial
Fig. 4. Peritonitis results in increased leakage of proteins into the peri- nitric oxide synthase (eNOS) expression in tissues and NOS activity.
toneal cavity. Despite the presence of an inflammatory process, perito- Data are from reference [14].
neal lymphatic flow is not increased during peritonitis. Data are from
reference [13].
suggested by high dialysate/plasma ratios of sodium.
These data suggest that a local production of NO, medi-
Table 3. Changes in selected mediators and mediator enzymes ated by different NOS isoforms, might play a role in theduring peritonitis
transport changes occurring in peritonitis.
Parameter Change References This is further strengthened by studies examining the
NO synthase (inducible) ↑ [14] effect of inhibition of NO synthesis on peritoneal trans-
NO synthase (non-inducible) ↑ [14] port during peritonitis. Breborowicz et al assessed thePGE2 ↑ [9, 16, 17]
effect of an inhibitor of nitric oxide synthesis, NG-nitro-6-keto-PGF1  ↑ [9, 16, 17]
Thromboxane B2 ↑ [9, 16] l-arginine methyl ester (L-NAME), on peritoneal trans-
Interleukin-1 ↑ [23, 32] port during peritonitis induced by intraperitoneal LPSInterleukin-6 ↑ [16, 23]
in rats [15]. In the presence of L-NAME, LPS did notInterleukin-8 ↑ [17, 20]
Interleukin-10 ↑ [32] induce the expected changes in transperitoneal transport
Transforming growth factor-beta ↑ [23] of small and large solutes and did not cause a significantFibroblast growth factor ↑ [23]
decline in net UF. L-NAME given intraperitoneally re-TNF- ↑ [21, 32]
INF- ↑ [32] duced both local and systemic production of nitric oxide,
Hyaluronan ↑ [26–29] which might explain its effects on peritoneal transport.
The increased expression of NOS during peritonitis and
the prevention of the transport changes with the NOS
inhibitor L-NAME suggest that nitric oxide is an impor-
Pathophysiology tant mediator of changes in peritoneal transport during
Various inflammatory and vascular mediators are re- peritonitis.
leased into the peritoneal cavity during peritonitis. How- Validation of the above formulation by measurements
ever, those involved in governing changes in peritoneal of peritoneal effluent nitrate or nitrite (as measures of
permeability to small solutes and protein remain incom- local NO production) has been difficult in both clinical
pletely defined (Table 3). [9] and experimental studies [16]. Studies of the perito-
Experimental observations suggest that changes in ni- neal effluent of patients with peritonitis did not uncover
tric oxide (NO)-mediated vascular tone and permeability any evidence of early changes in NO synthesis [9]. In 15
might be involved in the loss of UF during peritonitis [14]. patients with peritonitis, Douma et al found no evidence
In a model of acute peritonitis in rats, Combet et al for local production of nitrite or nitrate [9]. However,
observed that compared with controls, rats with peritoni- the MTAC of cyclic guanosine monophosphate (cGMP)
tis had a higher removal of plasma urea, a faster glucose was elevated 48 to 72 hours after the onset of peritonitis,
absorption, high protein loss and a loss of UF [14]. Acute which suggests the synthesis of NO. These clinical obser-
peritonitis in rats induced a major increase in total NO vations were interpreted to imply that the role of NO
synthase (NOS) activity, which was inversely correlated in mediating the changes during peritonitis is delayed
with free-water permeability. The increased NOS activ- [9]. Peritoneal effluent studies, however, may be insensi-
ity was mediated by both inducible (Ca2-independent) tive to localized changes in NO synthesis uncovered in
and endothelial (Ca2-dependent) NOS isoforms (Fig. 5). tissue expression experiments. Increased NO synthesis
In contrast, aquaporin-1 expression was unchanged in rats indeed may be responsible for the increased functional
vascular surface area caused by peritoneal inflammation.with peritonitis, but impaired aquaporin function was
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Fig. 7. Addition of hyaluronan (HA) to dialysis solutions during perito-
nitis has no effect on the dissipation of the glucose gradient, but still
results in some attenuation of the degree of negative net ultrafiltration.
Symbols are () peritonitis  HA; () peritonitis. Data are from
reference [32].Fig. 6. Peritonitis is associated with increases in peritoneal protein
clearance and intraperitoneal secretion of prostaglandin E2 (PGE2).
Both of these changes are corrected by the intraperitoneal administra-
tion of indomethacin (IND) in the rabbit. Data are from reference [17].
noma growth stimulating activity (huGRO), and the
growth factors transforming growth factor- (TGF-)
and fibroblast growth factor (FGF) [16, 20–23]. The dial-The alterations in peritoneal permeability characteris-
ysate concentrations of IL-8 [20] and of huGRO [22]tics during peritonitis can be explained in part also by
were related to the maximum number of neutrophils inthe increased concentrations of prostaglandins and cyto-
effluent. Also, TGF- complementary DNA (cDNA) mol-kines in the dialysate [9]. In the acute phase of peritonitis
ecules per macrophage were significantly greater thanthe vasodilating prostaglandins E2 (PGE2) and 6-keto-
those of macrophages in non-infected peritoneal efflu-PGF1 were increased tenfold, while the increase in the
vasoconstrictor thromboxane 2 (TxB2) was only fivefold ent. Relationships were found between the increase in
[16]. Using multiple regression analysis, the change in the effective peritoneal surface area and that of dialysate
dialysate PGE2 was related to the change in the intrinsic IL-6 and TNF [16]. These observations suggest an active
peritoneal permeability to macromolecules. No relation- release of proinflammatory cytokines and sclerogenic
ship was found between the increase in prostaglandin con- growth factors during peritonitis. It is unknown whether
centrations and the transport of 2-microglobulin, re- these factors might affect the physiological properties
flecting the effective peritoneal surface area. The above of the peritoneal membrane after recovery from the in-
findings were reconfirmed during standardized four-hour fection.
dialysis exchanges [9]. The clinical observations were du- Hyaluronan (HA) is a polysaccharide that forms a crit-
plicated by Peng et al in an E. coli induced peritonitis ical component of extracellular matrices. HA is present
model in the rabbit [17]. Inhibition of prostanoid produc- in high concentrations in tissues undergoing remodeling
tion by intraperitoneal administration of indomethacin and morphogenesis, and it appears to have an important
resulted in lower dialysate concentrations of the vasodi- role in the early stages of wound healing. Effluent hyalur-
lating prostaglandins both in patients [18] and in rats [17]. onan concentrations in non-infected CAPD patients are
In the latter study an effect on peritoneal permeability to higher than those in serum [24–29], suggesting local pro-
protein was found (Fig. 6), but this was absent in the study
duction, probably by mesothelial cells [28]. Patients with
in humans [18]. Indomethacin in non-peritonitis patients
a large effective vascular surface area appeared to haveinhibited 6-keto-PGF1, but had no effects on peritoneal higher effluent concentrations of hyaluronan than thosetransport [19]. It follows from the above findings that
with low D/P creatinine ratios [29]. Peritonitis causes aprostaglandins are mainly involved in large pore perito-
marked increase in dialysate hyaluronan [26–29]. This ef-neal transport during peritonitis, but have no effect on
fect might be mediated by IL-1 [28]. Addition of exoge-the effective peritoneal surface area, which determines
nous hyaluronan to dialysis solutions causes higher ultra-the transport of low molecular weight solutes like glucose.
filtration rates in rats, both in non-infected animals [30]Bacterial peritonitis leads to the release of proinflam-
and during peritonitis [31, 32], without any changes inmatory cytokines from resident and infiltrating cells in
the dissipation of the osmotic gradient (Fig. 7).the peritoneal cavity, which may have effects on trans-
It is clear from the studies reviewed in the previousport (Table 2). Various studies have shown marked in-
section that the functional changes observed during peri-creases in dialysate concentrations of the proinflamma-
tonitis are due to a combination of factors that act eithertory cytokines interleukin-1 (IL-1), tumor necrosis fac-
synergistically or antagonistically to modify and modu-tor- (TNF) and IL-6, the chemokines IL-8, monocyte
chemoattractant peptide-1 (MCP-1) and human mela- late peritoneal transport (Fig. 8).
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quired catheter removal or antibiotic therapy for more
than three weeks. After severe peritonitis, affected pa-
tients had higher increase in D/P creatinine over a period
of two years than patients who experienced no severe
infection [34].
Use of icodextrin
Icodextrin can be expected to induce the highest ultra-
filtration rates in patients with a large effective or ana-
tomical vascular surface area reflected in a high D/P cre-
atinine. This is because the removal of icodextrin from
the peritoneal cavity is predominantly via convective
pathways (lymphatic absorption), while that of glucose
is mainly by diffusion. A large vascular surface area al-
lows high ultrafiltration rates, but this effect is counter-
acted by a rapid dissipation of the osmotic gradient with
glucose-based solutions. In contrast the colloid osmotic
Fig. 8. Schematic of the interrelated effects of various mediators in- pressure gradient remains present during the dwell when
duced by peritonitis in inducing or modulating the transport changes icodextrin is used. Increased ultrafiltration rates in pa-observed during peritoneal inflammation.
tients with high D/P ratios or mass transfer area coeffi-
cients of creatinine have been described [38, 39]. This
effect also could be induced after intraperitoneal admin-
istration of nitroprusside [40]. Based on these findingsChronic effects of peritonitis
high ultrafiltration rates can be expected during peritoni-The effect of peritonitis on the long-term integrity of
tis. This indeed had been the clinical experience as re-the peritoneal membrane in peritoneal dialysis (PD) has
ported from various centers [abstracts; Dratwa et al, Peritbeen the subject of intense investigation, but a uniform
Dial Int 18(Suppl 2):S74, 1998; Dratwa et al, Perit Dial
consistent picture has not emerged. This is mainly due Int 17(Suppl 1):S31, 1997; Posthuma et al, J Am Soc Neph-
to the variability of the clinical syndrome, the wide range rol 8:270A, 1997] [41–43]. The findings of these studies
of severity, and the paucity of sequential studies in af- have been uniformly consistent: a decline in ultrafiltra-
fected patients. tion during peritonitis with the use of glucose-based dial-
Fussholler et al found that patients with a history of ysis solutions and a stable or increased ultrafiltration re-
peritonitis were not different from patients without a sponse to icodextrin-based solutions.
previous peritonitis episode in terms of D/P ratio and In a randomized study on the efficacy of icodextrin
mass transfer area coefficient of low molecular weight versus glucose in thirty-eight patients on automated peri-
solutes, lymphatic absorption rate, transcapillary ultra- toneal dialysis (APD), Posthuma et al had the opportu-
filtration, and net ultrafiltration [33]. Similarly, Wong et nity to prospectively compare the clinical efficacy of ico-
al observed that the longitudinal changes in peritoneal dextrin during episodes of peritonitis (abstract; ibid)
transport were independent of the history of peritonitis [42, 43]. Thirty peritonitis episodes occurred during fol-
[34]. The findings are different, however, after severe low-up. Daytime dwell UF decreased significantly during
peritonitis glucose, but remained stable in icodextrin pa-peritonitis episodes. The prospective longitudinal study
tients compared to non-peritonitis measurements (Fig. 9).of Davies et al showed that clusters or recurrences of
Serum icodextrin metabolites remained stable duringperitoneal infection caused a higher D/P creatinine and
peritonitis; serum maltose concentrations did not changea lower ultrafiltration after recovery, than the previous
from steady state levels, nor did total icodextrin levels.values obtained in a stable situation [35]. A similar effect
These findings have been corroborated experimentally bywas found by Selgas et al [36]. Szeto et al examined the
Wang et al [11]. Therefore, it can be concluded that thetransport changes that developed in patients with severe
use of icodextrin for the long dwells during peritonitis,peritonitis necessitating removal of Tenckhoff catheter
both in CAPD and APD induces more net ultrafiltration[37]. Of 51 patients who had undergone a successful re-
than glucose-based solutions, thereby strengthening theinsertion of catheter and resumed PD, 11 patients were
results of the pathophysiological studies.changed to long-term hemodialysis within eight months
after their return to CAPD. After resuming peritoneal
HIGH TRANSPORT AND UF FAILURE DURINGdialysis, a significant decline was found in net ultrafiltra-
CHRONIC PDtion volume and a trend toward a rise in D/P creatinine
(P  0.15). In a separate study, the same group investi- The transport abnormalities underlying ultrafiltration
failure during chronic PD are not monolithic and the co-gated severe peritonitis defined as an episode that re-
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Fig. 9. Peritonitis in patients on automated peritoneal dialysis (APD)
results in an accentuation of negative net ultrafiltration observed during
Fig. 10. Results of D/P creatinine at four hours obtained from repeatthe long daytime dwell with the use of glucose-based dialysis solutions.
peritoneal equilibrium tests (PETs) during chronic PD. All patientsIn patients using icodextrin for the daytime dwell, the positive net
had a minimum of 2 PETs during the follow-up, and many three toultrafiltration is maintained despite the occurrence of peritonitis. Sym-
four evaluations.bols are () non-peritonitis; () peritonitis. Data are from (abstract;
Posthuma et al, J Am Soc Nephrol 8:270A, 1997) [42, 43].
existence of synergistic derangements is a possibility that
has been recognized in the formulation of the clinical
guideline on ultrafiltration failure [4, 7]. A fast transport
status (high D/P ratio of low molecular weight solutes),
however, either alone or in combination with other alter-
ations in membrane function, remains the most common
underlying mechanism [4, 7].
Temporal changes in membrane function
Peritoneal ultrafiltration capacity and small-solute
transport characteristics are relatively stable in most pa-
tients treated with PD for three to five years [abstract; Fig. 11. Results of D/D0 glucose at four hours obtained from repeat
PETs during chronic PD. All patients had a minimum of two PETsHung, Perit Dial Int 22(Suppl):S10, 2002] [2, 34–36]. Wong
during the follow-up, and many three to four evaluations.et al have recently examined longitudinal changes in
the peritoneal equilibration test in 64 patients [34]. No
significant change in peritoneal solute transport was seen
after two years. A centripetal pattern of the change in alterations. Based on a clinical definition Heimburger
D/P creatinine was observed which probably reflects a et al found that the prevalence of ultrafiltration failure
regression-to-mean phenomenon. Similar results have increased from 3% during the first year of CAPD to
been reported by Hung in 76 patients (abstract; ibid) 31% after six years of treatment [46]. Using a standard-
and by one of us in a study of 230 paired peritoneal ized dwell, this complication was found in 35% of pa-
equilibrium tests (PETs) in CAPD patients from Turkey tients treated with PD for more than four years (abstract;
(Figs. 10 and 11) (unpublished observations). Smit et al, Perit Dial Int 22:117, 2002). Continuous ex-
While the overall pattern of peritoneal transport is posure of the peritoneum to hypertonic glucose solu-
stable, some patients treated with PD for four years or tions may have a causative role in changes in peritoneal
more develop increasing diffusive transport of low mo- function. Davies et al have recently presented evidence
lecular weight solutes leading to a decreased net ultra- suggesting that increased exposure to glucose precedes
filtration on glucose-based solutions. This suggests an changes in solute transport in a selected group of long-
enlargement of the vascular peritoneal surface area. An term PD patients [47]. Of 22 patients who were treated
increase in the number of peritoneal blood vessels with continuously for five years, 13 had stable solute transport
the duration of PD has been described [44]. Their density (D/P creatinine at start, 0.67; at 5 years, 0.67), whereas
per unit length of peritoneum was significantly higher 9 had a sustained increase (D/P creatinine at start, 0.56;
for patients with membrane failure [45], and implies the at 5 years, 0.77). Compared with the stable patients, those
with increasing transport had earlier loss in residual renalpresence of a morphological substrate for the functional
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function and were exposed to significantly more hyper-
tonic glucose during the first two years of treatment that
preceded the increase in solute transport [47]. Further
increases in glucose exposure were observed as solute
transport continued to rise. In this selected group of
long-term survivors on PD, an increase in solute trans-
port with time was preceded by increased peritoneal
exposure to hypertonic glucose. Besides many other ob-
servations, this is supportive evidence that hypertonic
glucose may play a causative role in alterations in perito-
neal membrane function.
A high lymphatic absorption rate can contribute to
ultrafiltration failure [33, 46], and this is illustrated in
Fig. 12. Net ultrafiltration response to () icodextrin and () 2.5%the recent report by Smit et al (abstract; ibid) [51]. In a
dextrose by PET transport type. Redrawn from data in (abstract; Wolf-cross sectional study of 20 long-term PD patients with
son et al, J Am Soc Nephrol 12:317A, 2001).
UF failure, a mixed defect (an increase in small solute
diffusive transport with a simultaneous increase in lym-
phatic absorption) was observed in 12 patients and unique
abnormalities were observed in only 6. These findings patients with ultrafiltration failure was recognized early
after the introduction of icodextrin-based peritoneal di-indicate that increased small solute diffusive transport
remains the most commonly observed transport alter- alysis solutions. Stein et al described the course of 61
patients with ultrafiltration failure treated with icodex-ation and that synergistic changes in lymphatic absorp-
tion may occur more commonly than previously as- trin. The majority of patients could be maintained on
PD after the addition of icodextrin and only eight pa-sumed. It must be emphasized that these measurements
were done using the disappearance rate of intraperitone- tients were subsequently transferred to HD because of
recurrent ultrafiltration failure after a minimum of eightally administered macromolecular tracers, which are taken
up into the lymphatics that drain the peritoneal cavity, months on icodextrin [50].
Wilkie et al provided a long-term follow-up of re-but also in peritoneal interstitial tissue. It is unknown
whether lymphatic absorption from the peritoneal cavity sponse to icodextrin in 33 patients with clinical ultrafil-
tration failure as defined above. CAPD technique sur-increases with the duration of peritoneal dialysis.
vival was extended by a median of 22 months in patients
Use of icodextrin who would have otherwise required transfer to hemodi-
alysis [51]. Johnson et al recently examined the use ofBecause of its large molecular weight, icodextrin ex-
hibits a kinetic profile that makes it uniquely suited for icodextrin as salvage therapy for refractory fluid over-
load in a prospective, open-label study of 17 patients onuse as an alternative to glucose in patients with increased
small solute diffusive transport. This has been discussed peritoneal dialysis [52].
Icodextrin was substituted for 4.25% dextrose for thein the section on peritonitis and has recently been con-
firmed by other groups, both in observational studies long dwell exchange in patients were on the verge on
being transferred to hemodialysis because of symptom-[48] and in a randomized double-blind controlled trial
(Fig. 12) (abstract; Wolfson et al, J Am Soc Nephrol 12: atic fluid retention that was unresponsive to fluid restric-
tion, loop diuretic therapy, hypertonic dextrose exchanges,317A, 2001). The increase in ultrafiltration volume was as-
sociated with an increase in convective transport of low and dwell time optimization. Icodextrin increased daily
peritoneal ultrafiltration (UF) by 599 mL (885  210molecular weight proteins such as 2-microglobulin (ab-
stract; Opatrna et al, J Am Soc Nephrol 12:314A, 2001) mL to 1454  215 mL, P  0.05) and reduced mean
arterial pressure by 10 mm Hg (106  4 mm Hg to 96 [48, 49] and leptin (abstract; Opatrna, ibid) [56]. Similar
results on the relationship between peritoneal transport 4 mm Hg, P  0.05) [52]. Overall PD technique survival
was prolonged by a mean of 11.6 months (95% CI 6.0status and icodextrin-induced ultrafiltration have re-
cently been reported by Pecoits-Filho et al [abstract; to 17.3 months). Diabetic patients experienced improve-
ment in glycemic control as evidenced by a decrease inPerit Dial Int 22(Suppl):S13, 2002], who additionally sug-
gested a correlation between high transport status and hemoglobin A1c from 8.9 0.7% to 7.9 0.7%. Seven of
the 12 patients required a reduction in insulin dose [52].effluent IL-6 and VEGF. A relationship between dialy-
sate VEGF and peritoneal transport also was found by In summary, a state of increased diffusive transport
of small solutes appears to be operative in most casesVan Esch et al in patients during their first half year of
PD [abstract; Perit Dial Int 22(Suppl):S16, 2002]. of clinical ultrafiltration failure. In patients with acute
peritonitis, the increase in small solute diffusive transportThe role of icodextrin in the clinical management of
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macromolecules during longitudinal follow-up of peritonitis in con-appears to be the predominant and only mechanism un-
tinuous ambulatory peritoneal dialysis. J Lab Clin Med 122:686–
derlying the decline in ultrafiltration capacity. In patients 696, 1993
17. Peng H, Cheung AK, Reimer LG, et al: Effect of indomethacinwho develop ultrafiltration failure during long term PD,
on peritoneal protein loss in a rabbit model of peritonitis. Kidneyhigh diffusive transport of small solutes remains the most
Int 59:44–51, 2001
commonly observed underlying cause. In a number of 18. Zemel D, Struijk DG, Dinkla C, et al: Effects of intraperitoneal
cyclooxygenase inhibition on inflammatory mediators in dialysatecases, however, a synergistic ancillary mechanism (such
and peritoneal membrane characteristics during peritonitis in con-as lymphatic absorption) appears to be operative as well.
tinuous ambulatory peritoneal dialysis. J Lab Clin Med 126:204–
Icodextrin has been found to be clinically effective in 215, 1995
19. Douma CE, de Waart DR, Zemel D, et al: Prostaglandin inhibi-restituting UF in both patients with peritonitis and pa-
tion by intraperitoneal indomethacin has no effect on peritonealtients with ultrafiltration failure during chronic PD. This
permeability during stable CAPD. Nephrol Dial Transplant 16:
clinical success of icodextrin is due to its unique mecha- 803–808, 2001
20. Zemel D, Krediet RT, Koomen GCM, et al: Interleukin-8 duringnism of action as a colloid osmotic agent.
peritonitis in patients treated with CAPD; an in vivo model of
acute inflammation. Nephrol Dial Transplant 9:169–174, 1994Reprint requests to Salim Mujais, M.D., Renal Division, Baxter
Healthcare Corporation, 1620 Waukegan Rd, MPGR-D1, McGaw Park, 21. Zemel D, Imholz ALT, de Waart DR, et al: Appearance of tumor
necrosis factor- and soluble TNF-receptors I and II in peritonealIllinois 60085-9815, USA.
E-mail: mujaiss@baxter.com effluent of CAPD. Kidney Int 46:1422–1430, 1994
22. Tekstra J, Visser CE, Tuk CW, et al: Identification of the major
chemokines that regulate cell influxes in peritoneal dialysis pa-
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